Die Universität Witten/Herdecke ist durch das NRW-Wissenschaftsministerium unbefristet staatlich anerkannt und wird – sowohl als Institution wie auch für ihre einzelnen Studiengänge – regelmäßig akkreditiert durch:
Forschung
EU-Projekte
EU
1 / 4
Unter dem Titel „Horizont 2020“ hat die Europäische Union ihre Förderungen für Forschung und Innovation gebündelt. Das Förderprogramm läuft bis 2020 und vereint verschiedene ehemalige Forschungs-Rahmenprogramme. Insgesamt stehen über „Horizont 2020“ gut 70 Millionen Euro zur Finanzierung innovativer Wissenschaftsvorhaben zur Verfügung. Schwerpunkte des Programms sind die Themenkomplexe „Wissenschaftsexzellenz“, „Führende Rolle der Industrie“ und „Gesellschaftliche Herausforderungen“.
Hier finden Sie eine Übersicht aktueller und ehemaliger EU-Projekte an der UW/H:
Übersicht aktueller und ehemaliger EU-Projekte an der UW/H:
Improving health services for European citizens with dementia: Development of best practice strategies for the transition from ambulatory to institutional long-term care facilities
Projektleiterin: Prof. Dr. phil. Gabriele Meyer (since 3/2013 Martin Luther University Halle-Wittenberg)
Kurzbeschreibung:
Given the increasing number of patients/consumers with dementia, political action is urgently required to prepare the health care services throughout Europe to deliver cost effective high quality long-term care to people concerned. There is a lack of clinical research data of patients/consumers and informal caregivers to develop best practice strategies for long-term care. RightTimePlaceCare intended to deliver best practice strategies for need-tailored dementia care throughout the dementia care sectors and aimed to preserve best available health outcomes for both patients/consumers with dementia and their informal caregivers at affordable cost-benefit ratios.
RightTimePlaceCare described and analysed the European health, social care and welfare systems, advocacy and informal caregiver support systems for patients/consumers with dementia and intersectorial communication. A European survey assessed the factors influencing the time of admission to institutional long-term nursing care facilities, investigated living conditions and gathered clinical data of patients/customers with dementia and their informal caregivers in long-term formal professional home care and institutional nursing care facilities, and the related economic impact. Consecutively best practice strategies have been developed for intersectorial arrangements needed to improve the effectiveness and efficiency of integrated health care in European dementia care systems, and recommendations for best practice models or interventions in long-term care facilities. RightTimePlaceCare tried to advance the state of the art in health systems research in dementia care and intended to improve cooperation between researchers to promote integration and excellence of European dementia care research. The knowledge generated by RightTimePlaceCare has aimed to empower the policy and decision makers to manage and reform dementia health care systems in view of common challenges and within the common framework of the EU.
More information
Polypharmacy in chronic diseases: Reduction of inappropriate Medication and Adverse drug events in elderly population by electronic Decision Support
Projektleiter: Prof. Dr. med. Andreas Sönnichsen
Kurzbeschreibung:
Chronic multimorbidity is rising in our aging population, and inappropriate polypharmacy of older patients poses a serious threat to health and wellbeing. Furthermore it involves extensive costs in all health care systems. While there exists only limited evidence regarding the benefit of polypharmacy, the evidence regarding potential harm of inappropriate medication is increasing. This clearly indicates that there is a strong need to reduce inappropriate drug therapy and polypragmatic drug prescription. Diverse heterogeneous approaches to reduce polypharmacy and inappropriate prescribing have been proposed, but none of these have been evaluated regarding practicability in primary care and clinically relevant endpoints within a sufficiently powered randomized controlled trial. This leads us to our principal hypothesis that
The reduction of polypharmacy and inappropriate prescribing according to current best evidence will improve the clinical outcome of elderly patients with multiple chronic diseases.
This hypothesis needs to be tested in a sufficiently powered randomized controlled trial with relevant clinical outcome as primary endpoint. PRIMA-eDS is setting out to first gather current best evidence regarding drug treatment of multimorbid elderly patients, and then test the hypothesis stated above in a thoroughly planned randomized controlled trial with hospital admission rate and mortality as primary clinical outcomes.
The objectives of our project to optimise management of elderly patients with multiple chronic diseases and polypharmacy are:
- to carry out a systematic review of the literature, evaluating and defining current best evidence regarding the treatment of elderly patients with multiple chronic diseases, specifically addressing the problem of polypharmacy in the treatment of the most common chronic diseases in elderly populations
- to develop an electronic decision support tool (eDS-tool) to aid physicians and patients to make use of current best evidence when coming to a shared decision regarding multiple drug treatment of the most common chronic diseases in elderly populations
- to test the efficacy of the eDS-tool in an appropriately powered, multinational, multicentre cluster-randomised controlled trial with a composite of hospital admission and mortality as the primary endpoint, and mortality and adverse drug events as safety endpoints
- to optimise the eDS-tool with the results of the randomised controlled trial, and make it available for widespread use within and outside of Europe
WP-Projektleiter und Konsortium-Mitglied: Prof. Dr. med. Marc Maegele
Kurzbeschreibung:
Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 6000 patients, which will be used for better characterization of TBI and for Comparative Effectiveness Research (CER). The generalisability of results will be reinforced by a contemporaneous registry level data collection in 20-40,000 patients. The conceptual approach is to exploit the heterogeneity in biology, care, and outcome of TBI, to discover novel pathophysiology, refine disease characterization, and identify effective clinical interventions. Key elements are the use of emerging technologies (biomarkers, genomics and advanced MR imaging) in large numbers of patients, across the entire course of TBI (from injury to late outcome) and across all severities of injury (mild to severe). Improved characterization with these tools will aid Precision Medicine, a concept recently advocated by the US National Academy of Science, facilitating targeted management for individual patients. The consortium includes leading experts and will bring outstanding biostatistical and neuroinformatics expertise to the project. Collaborations with external partners, other FP7 consortia, and international links within the International Initiative for Traumatic Brain Injury Research will greatly augment scientific resources and broaden the global scope of research. We anticipate that the project could revolutionize the view of TBI, leading to more effective and efficient therapy, thus improving outcome and reducing costs. These outcomes reflect the goals of CER to assist consumers, clinicians, health care purchasers, and policy makers to make informed decisions, and will improve healthcare at both individual and population levels.
WP-Projektleiter und Konsortium-Mitglied: Prof. Dr. med. Marc Maegele
Kurzbeschreibung:
According to the World Health Organisation, injuries are the leading killers of young people and remain one of the world’s biggest contributors to the global burden of disease. Despite a continuous improvement in medical care, outcomes for critically injured trauma patients remain poor with severe bleeding, brain injury, tissue damage and multiple organ failure linked to high mortality and disability. Since clotting disorders following trauma such as coagulopathy further worsen bleeding control and hampers emergency surgery, almost half of all trauma fatalities result from haemorrhage. Its current treatment is often based on empirical ”blind” administration of blood products with large variations between trauma centres.
The TACTIC project aims to specify underlying mechanisms of coagulopathy, to compare European transfusion strategies, to develop personalised transfusion therapies, and to conduct a comparative clinical trial (iTACTIC) for comparing outcomes of viscoelastic haemostatic assay (VHA)-guided versus optimised conventional coagulation test resuscitation. Research findings will deliver clinical guidelines for the treatment of coagulopathic bleeding. For these purposes, trauma centres in Amsterdam, Cologne, Copenhagen, London, Oslo, and Oxford collaborate and realise site-specific work packages to achieve a quantum step in the global health care management of coagulopathic trauma patients. It is expected to reduce trauma haemorrhage-related mortality by approximately ten percent, saving 30.000 lives per year as well as significantly reducing hospital and societal costs.
Publication:
Schäfer N, Driessen A, Fröhlich M, Stürmer EK, Maegele M; TACTIC partners. Diversity in clinical management and protocols for the treatment of major bleeding trauma patients across European level I Trauma Centres. Scand J Trauma Resusc Emerg Med. 2015 Oct 1;23:74. doi: 10.1186/s13049-015-0147-6.
Projektleiter: Prof. Dr. Petra Thürmann | Dr. Sven Schmiedl
Kurzbeschreibung:
Das PROTECT Projekt (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) ist ein europäisches Projekt mit dem Ziel, innovative Methoden für die Erhöhung der Arzneimittelsicherheit zu entwickeln.
PROTECT untersucht die Leistungsfähigkeit der Methoden, die zur Risikoerkennung und -abwehr bei (in der EU) zugelassenen Arzneimitteln verwendet werden. In verschiedenen Arbeitsgruppen sollen innovative Methoden entwickelt und validiert werden für (i) den Einsatz von modernen Kommunikationstechnologien für die Erfassung von Arzneimittelverbrauchsdaten, (ii) eine frühere und proaktive Entdeckung von Risikosignalen, (iii) das Design, die Durchführung und die Auswertung von Arzneimittelsicherheitsstudien und (iv) die kontinuierliche Risiko/Nutzen-Überwachung, insbesondere mit Hilfe von graphischen Methoden.
Die europäische Arzneimittelbehörde (EMA) in London koordiniert das Konsortium, das aus 34 öffentlichen und privaten Partnern besteht. Der Lehrstuhl für Klinische Pharmakologie ist seit 2013 offizieller PROTECT-Partner und untersuchte im Rahmen von Sekundärdatenanalysen diverse Fragestellungen unter anderem zu inhalativen Wirkstoffen, die zur Therapie von Asthma und COPD eingesetzt werden. Beispielsweise wurden der off-label Gebrauch dieser Wirkstoffe bei Kindern, saisonale Schwankungen im Verordnungsverhalten, Änderungen im Verordnungsverhalten unter besonderer Berücksichtigung der Leitlinienadhärenz oder auch die Vergleichbarkeit der in klinische Studien eingeschlossenen Patientenpopulation mit einer „real life“ Patientenpopulation untersucht. Im Rahmen der internationalen Kooperationen wurden aber auch andere Wirkstoffklassen und deren mögliche Assoziation mit ausgewählten unerwünschten Ereignissen untersucht sowie systematische Reviews erstellt. In weiteren, primär methodischen Analysen wurde u.a. untersucht, inwieweit Ergebnisse pharmakoepidemiologischer Untersuchungen bei Nutzung verschiedener Datenbanken aus unterschiedlichen Ländern vergleichbar sind.
Projektleiter: Prof. Dr. Joachim Zweynert
Kurzbeschreibung:
Beginnend mit der Ausrufung des Ziels, das BIP bis zum Jahre 2020 zu verdoppeln, hat die russische Regierung seit etwa 2004 einen wirtschaftspolitischen Kurswechsel vollzogen, der die Stärkung der „Vertikale der Macht“ zunehmend auf den Bereich der Wirtschaft ausdehnt und sich dabei – etwa mit der Bildung großer Staatskooperationen – am Vorbild der ostasiatischen Developmental States orientiert. Das Teilprojekt geht der Frage nach, welche Zusammenhänge zwischen der kognitiven Krise im wirtschaftspolitischen Diskurs, dem Erstarken staatszentrierter und nationalistischer ökonomischer Ideen und dem Wandel in der Wirtschaftspolitik bestehen und welcher Frames sich die Regierung und regierungsnahe Schlüsselakteure bedienen, um der neuen wirtschaftspolitischen Doktrin Legitimität zu verschaffen.